

Summary of the International Conference on Onco-Nephrology: an emerging field in medicine

Capasso A, Benigni A, Capitanio U, Danesh FR, Di Marzo V, Gesualdo L, Grandaliano G, Jaimes EA, Malyszko J, Perazella MA, Qian Q, Ronco P, Rosner MH, Trepiccione F, Viggiano D, Zoccali C, Capasso G, International Conference on Onco-Nephrology Participants: Akitaka A, Aлахoti A, Alexander TR, Altucci L, Amer H, Barone V, Biancone L, Bonventre JV, Camussi G, Ciardiello F, Caraglia M, Cartenì G, Cervantes A, Citterio F, Cosmai L, Daniele B, D'Errico A, De Vita F, Ereditato A, Falco G, Fouque D, Franco R, Gallieni M, Gambaro G, Kuo C, Launay-Vacher V, Maiello E, Mallamaci F, Marino G, Martinelli E, Matarese G, Matsubara T, Messa P, Messina C, Mirone V, Morgillo F, Costa AN, Orditura M, Pani A, Perna A, Pisano C, Pitts T, Porta C, Procopio G, Remuzzi G, Russo D, Siu LL, Stadler W, Troiani T, Weisz A, Więcek A, Xiaoqiang D, Zecchino O.

Abstract

Onco-nephrology is an emerging field in medicine. Patients with cancer may suffer from kidney diseases because of the cancer itself and cancer-related therapy. It is critical for nephrologists to be knowledgeable of cancer biology and therapy in order to be fully integrated in the multidisciplinary team and optimally manage patients with cancer and kidney diseases. In a recent international meeting, the key issues in this challenging clinical interface were addressed, including many unresolved basic science questions, such as the high tumor incidence in kidney transplant recipients. To this end, 70 highly qualified faculty members were gathered from all over the world to discuss these issues in 8 plenary sessions, including 5 keynote lectures. In addition, 48 young nephrologists and oncologists were invited to present their original observations that were highlighted in 2 large poster sessions.

Keywords: acute kidney injury, cancer chemotherapy, chronic kidney disease, nephrotoxicity, renal cell carcinoma.

Introduction

Cancer and kidney disease are both associated with significant morbidity and mortality.¹ Over the past decade, nephrologists, oncologists, and other clinicians recognized kidney disease and electrolyte/acid-base disturbances as complications of a malignant tumor. Moreover, chronic kidney disease (CKD) is associated with an increased cancer risk, making the relationship bidirectional. The importance of this cancer–kidney disease connection has prompted the creation of the subfield “onco-nephrology” (Figure 1).²

Both acute kidney injury (AKI) and CKD are prevalent in patients with cancer.^{3, 4, 5} Incidence and severity of AKI varies depending on type/stage of cancer, treatment regimen, and underlying comorbidities.^{4, 5, 6} Patients with incident cancer have 1- and 5-year AKI risk of 17.5% and 27%, respectively.⁷ Critically ill patients with cancer are at an even higher risk, with ~13% to 54% of patients developing AKI and 8% to 60% requiring dialysis.^{8, 9} As observed in the Renal Insufficiency and Cancer Medications (IRMA) Study 1 and 2, patients with cancer had a stage 3 CKD prevalence of ~12%.^{10, 11} In other cancer cohorts, stage 3 CKD was observed in ~13% to 30% of patients.^{12, 13}

Major risks of AKI include cancer-related metabolic disturbances, tissue deposition of paraproteins, treatment with nephrotoxic anticancer drugs, and hematopoietic stem cell transplantation.¹⁴ Total and partial nephrectomy for kidney cancer also increases the risk of acute kidney disease/CKD.¹⁵

Morbidity/mortality is higher in patients with cancer and kidney diseases,^{6, 10} with the highest mortality in patients with dialysis-requiring AKI.⁴ Some patients with cancer and CKD may also have an increased risk of death.^{12, 13, 16} Mortality risk is highest for hematologic malignancies, gynecologic cancers, and renal carcinomas in the setting of CKD.^{12, 13}

Kidney disease increases the risk of systemic chemotherapy toxicity, jeopardizes continued cancer therapy, and limits patient participation in clinical trials. Temporary or permanent cessation of effective chemotherapeutic regimens allows unhindered tumor growth, whereas underdosing of potentially curative regimens or use of suboptimal alternatives reduces treatment efficacy.^{2, 5} Altered drug pharmacokinetics risk systemic toxicity, whereas uremia impairs immune surveillance, allowing cancers to grow/metastasize. It is also possible that anticancer drug nephrotoxicity leads to progression of AKI and/or CKD, contributing to all-cause mortality unrelated to cancer.

It is critical that clinicians and researchers from multiple specialties develop familiarity with onco-nephrology as the number of patients surviving cancer and kidney disease increases. To this end, the meeting was designed. The summary of the plenary sessions is reported below.

The full conference program and the video recordings of all presentations and discussions can be found at the following website: <https://www.en.fondazione-menarini.it/Home/News/Onco-Nephrology-an-Emerging-Field-in-Medicine/Presentation>.

Advanced technologies

Researchers worldwide base their experiments using cancer cells in vitro, but to acquire a comprehensive understanding of the complexity of cancer biological processes, in vivo experiments are required. In cancer translational research and in the development of new therapeutics, many important advances have been accomplished by the use of patient-derived xenografts, that is, patient-derived tumors transplanted in immunocompromised mice¹⁷ with the advantage of recapitulating intra- and intertumor heterogeneity.¹⁸ However, the absence of an immune system in these mice limits their use to study immune-based treatments.¹⁹ With immunotherapy likely being a permanent component of the anticancer arsenal, better in vitro and in vivo preclinical models are needed.^{20, 21} Ex vivo spheroid models have been generated to screen immunotherapy combinations, but such approach is also limited by lacking the ability to study the tumor-immune system interactions.²² Likewise, the use of syngenic murine-derived cancer models in immune-competent mice is regrettable on the basis of current knowledge of the molecular heterogeneity of human malignancies, limited available models, and differences between mouse and human immunology.^{23, 24, 25}

To gain a better biological understanding of the human immune system, “hematopoietic humanized mice” have been developed. These models provide an opportunity to study the human biological process that would not otherwise be possible.

Currently several humanized mouse models are being used to study human diseases.²⁶ They can be generated by transplantation of (i) human peripheral blood mononuclear cells, (ii) tumor infiltrating lymphocytes, (iii) CD34+ human hematopoietic stem, or (iv) transplantation of human fetal liver and thymus under the kidney capsule and injection of autologous fetal liver human stem cells.^{27, 28, 29}

Because of their immunosuppressed environment, these humanized models have shown to accept allogeneic tumors, providing a novel preclinical platform to study innovative therapeutic combination in cancer.³⁰

These models allow a comprehensive analysis of the human immune system, granting access to lymph nodes, spleen, and tumor tissues and providing more information about immune response. Immunotherapies have started a new era in cancer therapy, but the impressive immune-mediated responses are still limited to a minority of patients. Despite the encouraging results obtained in the clinical setting and the initial evidence of the importance of tumor mutation load and genetic alterations, we still lack the full understanding of mechanisms responsible for tumor immune rejection. Humanized mouse models can improve our knowledge and facilitated testing of novel therapeutic combinations.³¹

How to measure kidney function in patients with cancer

Measuring glomerular filtration rate (GFR) in patients with neoplasia is fundamental for profiling both the risk and the appropriate dose of chemotherapeutic agents. Ideally GFR should be measured using criterion standard, that is, by chromium-51-ethylenediaminetetraacetic acid (51Cr-EDTA) or technetium-99m–diethylenetriaminepentaacetic acid (99mTc-DTPA) or by inulin or iothalamate clearance³² (see Canadian Cancer Association: Glomerular Filtration Rate study, <http://www.cancer.ca>). However, these methods are time-consuming and costly. For this reason, in the vast majority of patients with cancer, GFR is estimated by creatinine-based formulas. Several studies in patients with cancer examined the reliability of current creatinine-based methods, namely, the Cockcroft-Gault equation, the 4-variable Modification of Diet in Renal Disease equation based on either uncalibrated creatinine or calibrated creatinine, and the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. Nevertheless, these studies focused on a specific type of cancer,^{33, 34, 35, 36} did not test the CKD-EPI equation,³⁷ and included a small number of patients.^{34, 36} The largest and most thorough study so far, by Janowitz et al.,³⁸ included >2000 patients with various types of cancers. The study tested all main creatinine-based GFR formulas as well as a new Janowitz equation validated against an established criterion standard such as 51Cr-EDTA. The new equation was slightly more precise than the CKD-EPI equation and showed no bias, denoting adequate accuracy.³⁸ A GFR calculator based on the Janowitz equation is available online at <http://tavarelab.cruk.cam.ac.uk/JanowitzWilliamsGFR/>. For extensive validation in diverse populations and the satisfactory accuracy and precision in patients with cancer, the CKD-EPI formula appears suitable for application in this population. If further validated in other large databases, the new equation³⁸ can emerge as the new standard of care for patients with cancer.

A formula based on the combination of creatinine and cystatin C measurements is the most reliable estimate of GFR in the general population and in patients with CKD,^{39, 40} but there is no adequate validation study of this formula in the population with cancer. Cystatin C is influenced by inflammation and cell turnover, and in B-cell non-Hodgkin lymphoma its synthesis is increased in immature dendritic cells,^{41, 42} making this marker a less than ideal GFR surrogate.

Future directions for the direct measurement of GFR in patients with cancer include the development of fluorescence methods for real-time GFR determination.⁴³ Specifically, dextrans of different molecular weight can be labeled by different fluorochromes and thus be used with 2-compartmental models to measure the plasma volume (unfiltered dextrans) and GFR (filtered dextrans). Furthermore, fluorescence could be detected at the level of the skin, thus avoiding taking blood samples. Theoretically, this method could easily and rapidly measure GFR and plasma volume and potentially estimate renal reserve (i.e., the increase in GFR after a protein meal or infusion of amino acids⁴⁴). This may be particularly useful in allowing for rapid dose adjustments of potentially toxic drugs. However, several questions remain regarding this new technology and it has yet to be implemented in clinical practice.

Cancer in patients with a solid organ transplant

Neoplasia is the third cause of mortality in transplant recipients, and its incidence has been increasing over the past decade.⁴⁵ These patients have a 3- to 5-fold increased risk of developing solid organ cancers and a 60- to 200-fold increased risk of skin cancers in comparison to the general population.⁴⁶ Immunosuppressive therapy is the main cause of this dramatic increase. Immunosuppression induces a significant increase in viral infections, and most of the posttransplant neoplasia is well known to be linked to the action of specific viruses.⁴⁷ In addition, immunosuppressive drugs may have direct effects on the development of particular types of cancer, as demonstrated for azathioprine.⁴⁸ Finally, immunosuppression can facilitate the process of tumor immune escape. The reduced ability of the immune system to control neoplastic cell growth might also explain the particular aggressiveness of neoplasia in this setting. Indeed, the mortality rate for any specific neoplasia is significantly higher in patients with a transplant than in the general population.⁴⁹

Given the high risk of neoplasia, prevention should be the main objective of clinical care in this patient population. In this perspective, the first aim is to exclude that either the organ or the patient has an occult neoplasm at transplantation.⁵⁰ Both donors' and recipients' screening has significantly changed in the last few years, because a general history of neoplasia does not represent per se a contraindication to transplantation, but is considered on a case-by-case basis.^{50, 51} Screening needs to be expanded to include the whole posttransplant period, aiming for a timely diagnosis, which is particularly relevant.⁵² Finally, available evidence suggests that in high-risk recipients the use of the mammalian target of rapamycin (mTOR) inhibitor-based immunosuppressive regimen might be beneficial.^{46, 52}

Cancer in patients with CKD

Albuminuria is well recognized as an independent risk factor for cardiovascular disease, especially in patients with diabetes and hypertension.^{53, 54}

Clinical and experimental evidence suggests that endothelial dysfunction, chronic inflammation, and transvascular leakage of macromolecules may be responsible for the association between albuminuria and cardiovascular disease.^{55, 56} In addition to this well-known connection, emerging evidence indicates that albuminuria is linked to an increased risk of cancer mortality. Studies using data from the Third National Health and Nutrition Examination Survey (NHANES III) demonstrated that albuminuria is associated with an

increased risk of cancer death from all causes, lung cancer, and prostate cancer in men 50 years and older. Interestingly, this association was present only in men, as it was not significant for any type of cancer in women of the same age.⁵⁷ In addition to this link, several studies have shown that baseline albuminuria is linked to increased cancer incidence. In one of these studies, subjects in the highest quartile of albuminuria were 8.3- and 2.4-fold more likely to receive a diagnosis of bladder and lung cancer, respectively.⁵⁸

Patients with CKD have a 5- to 15-fold increased risk of cardiovascular mortality.^{59, 60} In addition, population-based studies have demonstrated that patients with CKD are at a higher risk of cancer, even those with mild to moderate stages of CKD.⁶¹ Patients with moderate CKD have an increased risk of cancer mortality, especially those with liver and urinary tract cancer,⁶² while others have shown that modest reductions in GFR <60 ml/min per 1.73 m² are linked to an increased risk of cancer death.¹² In the latter study, the association between reduced kidney function and cancer death appeared to be specific for breast cancer and urinary tract cancer. Other large longitudinal studies have shown a correlation between the severity of CKD and cancer mortality. Specifically, mortality from liver cancer, kidney cancer, and urinary tract cancer increased incrementally with the severity of CKD.⁶²

These epidemiological data introduce a number of additional topics concerning the difficulties in cancer treatment, screening, and biopsy in patients with CKD. The treatment of cancer is difficult because of the reduced renal excretion of drugs and different pharmacodynamics/pharmacokinetics of anticancer drugs in patients with CKD. For screening cancer in patients with CKD, we rely on standard guidelines for screening in the general population: specific surveillance protocols await further validation, and at present, considerable differences among nephrologists exist.⁶³ Finally, the therapeutic and diagnostic strategies with regard to renal complications in patients with cancer are probably suboptimal at present. Renal biopsy has been recommended in case of glomerular damage (hypertension, edema, proteinuria, and hematuria), interstitial disease (eosinophiluria), vascular disease/vasculitis, or unresolved tubular disease.⁶⁴

Renal cancer: multidisciplinary treatment approaches

When Robson et al. initially described the management of renal cancer, surgery included the removal of the entire kidney.⁶⁵ Therefore, surgical extirpation was usually affected by a significant decline in renal function and an increased risk of cardiovascular morbidity. Nowadays, the maximum preservation of normal renal parenchyma is standard of care, when technically feasible.⁶⁶ Nonetheless, up to 40% to 50% of patients treated with radical nephrectomy and up to 10% to 15% of nephron-sparing surgery cases experience renal functional impairment at 1 year after surgery.⁶⁷

In cases of metastatic renal cell carcinoma (RCC), systemic therapy has evolved rapidly over the past decade (Table 168, 69, 70, 71, 72, 73, 74, 75, 76, 77). Cytokines have largely been replaced in current practice by tyrosine kinase inhibitors.⁷⁸ The mammalian target of rapamycin (mTOR) inhibitor therapy is nowadays considered largely inferior to vascular endothelial growth factor (VEGF)-based therapy, although it has a role in combination strategies.⁷⁸

Finally, vaccines have failed to show an improved survival to date.⁷⁸ More recently, combination strategies involving contemporary immunotherapy have emerged as key opportunities to further shift the treatment

landscape.⁷⁸ With the advent of new therapies, median survival for patients with good-to-intermediate- and poor-risk metastatic RCC has increased from 26, 14, and 7 months to 43, 23, and 8 months.⁷⁸

For all those reasons, functional outcomes, overall survival, and quality of life of cancer survivors gained increasing scientific attention in the past years.⁷⁹ Efforts have been made to clarify the pathophysiology and mechanisms underlying the development of CKD after nephron-sparing surgery or radical nephrectomy. Beyond the surgical aspects, much more emphasis has been placed to patients' comorbidities and baseline characteristics. That said, a multidisciplinary approach to the decision making in patients with a renal mass may maximize those outcomes (Figure 2). Unfortunately, nowadays such an approach is not pursued in many urological cancer centers. To investigate this aspect, the Kidney Cancer Young Academic Urologists Working party recently promoted an Internet-based survey with the aim to better understand how urologists take care of renal function.⁸⁰ Although virtually all urologists (98%) answered that renal function is a critical variable for decision making, the consultation of a nephrologist after surgery for a patient with established CKD risk factors is contemplated in merely 17% of the cases. This is even more important if we considered that only a quarter of the urologists acknowledged albuminuria and obesity as key determinants of postoperative CKD. Of note, the latest European guidelines do not suggest referring patients with RCC for a perioperative nephrological assessment. Conversely, the American guidelines recommend nephrology referral after urological treatment, at least when CKD and/or proteinuria is detected.

A multidisciplinary management according to patients' individual risk factors appears mandatory to shift from a purely surgeon-oriented point of view to a holistic consideration to further improve functional outcomes and quality of life of patients with RCC.^{81, 82}

Glomerular diseases associated with cancer

There is a strong association between cancer and glomerulonephritis.^{83, 84} One study⁵⁸ found that proteinuria is more frequent in patients with malignancies than in controls. Data from the Danish Kidney Biopsy Register show a higher incidence of cancer in patients with glomerulopathy than in the general population.⁸⁵

Membranous nephropathy is the most frequent cancer-associated glomerulonephritis.⁸⁶ The pathogenesis is due to subepithelial deposition of tumor antigens⁸⁷ associated with an enhanced immune reaction triggered by a malignant tumor.⁸⁸ Seronegativity to anti-phospholipase A2 receptor antibodies, immunohistochemical identification of IgG1 and IgG2 subclasses,⁸⁹ and >8 inflammatory cells per glomerulus are the main criteria to differentiate idiopathic membranous nephropathy from cancer-related membranous nephropathy.

Minimal change disease occurs in ~1% of patients with Hodgkin lymphoma, and the occurrence of focal segmental glomerulosclerosis is about one-tenth that of minimal change disease. Interleukin-13 serum levels seem to play an important role.⁹⁰ Minimal change disease and focal segmental glomerulosclerosis are also associated with solid tumors. VEGF has been potentially implicated in pathogenesis because of its ability to increase glomerular permeability.⁹¹

Rapid progressive glomerulonephritis can develop in patients with RCC, gastric cancer, and lung cancer. Conversely, patients with antineutrophil cytoplasmic antibody–associated (ANCA) vasculitis exhibit a higher risk of a malignant tumor than did the general population.⁹²

Membranoproliferative glomerulonephritis has been associated with solid tumors (lung, renal, and gastric); this is an immune complex disease caused by tumor antigen formation and the inability of the host to effectively clear these antigens.⁹³ It may also develop in the context of chronic lymphocytic leukemia, hairy cell leukemia, and B-cell non-Hodgkin lymphoma.

IgA nephropathy is associated with respiratory tract, oral mucosa, and nasopharyngeal cancer; RCC, and cutaneous T-cell lymphoma. It has been hypothesized that the invasion of the site-specific lymphoid-associated tissue by cancer cells leads to increased circulating levels of IgA because of overproduction of interleukin-6.⁹⁴

Nephrotoxicity from chemotherapy

Nephrotoxicity of conventional chemotherapeutic agents remains a significant problem in patients with cancer not only because of its impact on the survival of patients with cancer but also because of its dose-limiting effect on the adequate cancer treatment. Although nephrotoxicity is a major side effect of many chemotherapeutic agents, not all patients exposed to these agents develop kidney injury. This suggests the presence of several factors that could increase the patient’s risk of nephrotoxicity, including the patient’s age, intravascular volume depletion, and the presence of underlying AKI or CKD.⁹⁵

Conventional cytotoxic agents can cause nephrotoxicity by various mechanisms involving different parts of kidney anatomy including glomerulus, tubules, interstitium, and renal microvasculature with kidney manifestations ranging from an acute interstitial nephritis, focal segmental glomerulosclerosis, and hypertension to various electrolyte disorders, capillary leak syndrome, and thrombotic microangiopathy (TMA).¹³

Unfortunately, a subset of patients who develop nephrotoxicity can give rise to long-term complications such as chronic interstitial nephritis and CKD.

A major kidney complication of both mitomycin C and gemcitabine, 2 other important conventional chemotherapeutic agents, is the development of TMA. Interestingly, there are often findings of both acute and chronic TMA with these drugs. Whereas acute TMA is characterized by the formation of fibrin microthrombi in arteries, arterioles, and glomerular capillaries, chronic TMA is typically considered as sclerosis and “onion skin” appearance of arteries and arterioles. Mitomycin C–induced TMA is dose dependent,^{96, 97} whereas no clear relationship has been observed between the cumulative dose of gemcitabine and the risk of TMA. The underlying molecular mechanism of gemcitabine-induced TMA is not well established; it might involve both direct endothelial injury and diminished activity of a von Willebrand

factor named ADAMTS-13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13).⁹⁸

TMA has also been observed after treatment with VEGF inhibitors (such as bevacizumab) and inhibitors of VEGF tyrosine kinase domain (such as sunitinib).⁹⁹ These drugs, collectively called VEGF signaling pathway inhibitors, are plagued by an increased risk of cardiovascular disease due to vascular toxicity. Indeed, up to 42% of patients treated with bevacizumab and 34% of those treated with sunitinib develop hypertension (Micromedex and Lexicomp data). It has been even suggested that hypertension could be used as a sign of efficacy of VEGF signaling pathway inhibitors.¹⁰⁰ The mechanism of VEGF signaling pathway–induced hypertension is thought to involve nitric oxide regulation at the vascular level and reduced natriuresis at the level of the kidney.¹⁰⁰

Overall, a better definition of these interactions and further understanding of the molecular mechanisms whereby cytotoxic agents induce nephrotoxicity could provide better strategies to manage the kidney side effects of cytotoxic agents.

Molecular mechanisms of cisplatin-induced AKI

Cisplatin is an effective chemotherapeutic drug for a broad spectrum of solid organ malignancies. Its main dose-limiting side effect is its nephrotoxicity, which can present in many forms, the most serious and common being AKI.¹⁰¹ In early clinical use, a dose-related incidence of cisplatin-induced AKI was reported in 14% to 100% of patients, which decreased to 20% to 30% more recently with the use of saline hydration and diuresis.^{102, 103} Diuresis induced by the atrial natriuretic factor was also tested,¹⁰⁴ and parathyroidectomy is reported to exert some beneficial action.^{104, 105}

Cisplatin is traditionally believed to exert its antitumor effect through its interaction with DNA, leading to the formation of inter- and intrastrand cross-links, causing DNA synthesis and replication arrest.¹⁰⁶ However, recently an important question was raised on why kidney proximal tubular cells (PTCs) with relatively low rates of cell proliferation are especially prone to cisplatin-induced cytotoxicity. One recent persuasive explanation is that nephrotoxicity could result from mitochondrial damage and the release of high levels of mitochondrial reactive oxygen species.^{107, 108} This hypothesis is reinforced by the finding that along the proximal tubular epithelium, there are 2 membrane transporters that mediate cisplatin uptake in PTCs.¹⁰⁹

Cisplatin binds both nuclear and mitochondrial DNA, leading to cell cycle arrest and mitochondrial dysfunction.¹⁰² Because of their high-energy functions in active transport,^{110, 111} PTCs have high mitochondrial density and are particularly susceptible to cisplatin.

Mitochondria are highly dynamic organelles that continuously divide and unite through fission and fusion events to meet cell energy demands.¹⁰⁷ There is a large body of evidence demonstrating that NAD⁺-dependent deacetylase sirtuin 3 (SIRT3) maintains mitochondrial vitality by regulating processes such as energy homeostasis and antioxidant defenses.^{112, 113}

In experimental cisplatin-induced AKI, reduced SIRT3 levels are associated with oxidative stress and mitochondrial damage,¹¹⁴ leading to metabolic and functional impairment of PTCs.¹¹⁴ Mechanistically, cisplatin-induced reduction of SIRT3 levels triggers the upregulation of dynamin-related protein 1 and mitochondrial fission factor and the downregulation of optic atrophy 1, tipping mitochondrial dynamics toward fragmentation, along with loss of mitochondrial membrane potential and organelle disposal.¹¹⁴ The functional role of SIRT3 is highlighted by SIRT3-deficient mice experiencing more severe AKI and dying prematurely after receiving cisplatin.¹¹⁴ In wild-type mice with AKI, treatment with agents that increase SIRT3 expression and activity improves renal function and decrease tubular injury by preventing changes in mitochondrial dynamics.¹¹⁴

Enhancing SIRT3 preserves cellular cytoskeleton integrity, enabling the intercellular transfer of healthy mitochondria via tubulin-rich projections in cisplatin-injured PTCs.¹¹⁵ This reparative dialogue between adjacent PTCs favors bioenergetic cross talk and redox balance, which is abolished by SIRT3 silencing in PTCs.¹¹⁵

The natural outcome of these studies is the search for SIRT3-activating compounds. In this context, honokiol, a biphenolic compound derived from the bark of magnolia trees,¹¹⁶ has been shown to selectively increase SIRT3 and has anti-inflammatory and antioxidant effects.^{117, 118}

Furthermore, NAD⁺ precursors including nicotinamide, nicotinamide riboside, nicotinamide mononucleotide, or exogenous NAD⁺ have been found to be beneficial in cardiac and renal diseases^{119, 120} to the extent that nicotinamide supplementation has been associated with less frequent AKI in hospitalized patients.¹²¹

Immunotherapy and interstitial nephritis

Cancer immunotherapy exploits the immune system to fight tumor cells. The availability today of selective immune stimulants has finally solidified the original idea into a therapeutic success. The dark side of immunotherapy is the unavoidable presence of autoimmune effects, such as interstitial nephritis. Specifically, the class of immunotherapy drugs called immune checkpoint inhibitors results in clinically relevant kidney damage in 1% to 3% of patients; however, the percentage of subclinical interstitial nephritis might be much higher, up to one-third of patients with immune checkpoint inhibitors, according to autopsic series.¹²² Clearly this depends on our limited ability to identify this renal damage with classical blood tests: better biomarkers are thus needed. Immune checkpoint inhibitors could determine interstitial nephritis when T cells are primed by drugs associated with tubular damage, such as proton pump inhibitors and nonsteroidal anti-inflammatory drugs. The treatment is the same as it is for other T cell-mediated kidney injuries (such as after HIV infection and renal allograft rejection) and mostly depends on the use of steroids.¹²³

Electrolyte disorders in patients with cancer

Electrolyte disorders are commonly seen in patients with any form of cancer.¹²⁴ Table 2 lists the common etiologies of these electrolyte disorders.

Hyponatremia is the most common electrolyte disorder encountered in patients with cancer.^{125, 126, 127, 128, 129} Hyponatremia is associated with increased mortality and poor response to therapy.^{129, 130, 131, 132} The syndrome of inappropriate antidiuretic hormone may result from numerous malignancies and numerous chemotherapeutic regimens.^{133, 134, 135, 136} A diagnosis of hyponatremia may also be a marker of occult neoplasms.^{137, 138} Treatment of hyponatremia in patients with cancer is challenging and often suboptimal.¹³⁹ Blockade of the type 2 vasopressin receptor with tolvaptan may be particularly useful in cases of refractory syndrome of inappropriate antidiuretic hormone.¹⁴⁰ At least in patients with non–small cell lung cancer, normalization of serum sodium was associated with improved prognosis.¹⁴¹

Hypernatremia is less commonly seen and may be due to malignant involvement of the hypothalamic-pituitary axis or hypercalcemia-induced nephrogenic diabetes insipidus.^{129, 142} Hypernatremia is associated with substantial mortality risk.¹⁴³

Hypercalcemia is common in multiple myeloma and advanced stage cancers.¹⁴⁴

Survival in patients with cancer-associated hypercalcemia is dismal.^{145, 146} Hypercalcemia is most often caused by the release of parathyroid hormone–related peptide or local osteolysis (mediated by cytokines) (Figure 3).^{147, 148, 149, 150, 151} Treatment of cancer-associated hypercalcemia includes intravenous hydration to increase renal calcium excretion, followed by either bisphosphonate, calcitonin, or denosumab, to decrease the bone release of calcium.^{147, 152}

Hypokalemia results from gastrointestinal or renal losses (due to ifosfamide, cisplatin, non-K+–sparing diuretics, or rarely leukemia-associated lysozymuria).^{129, 133, 153, 154} Hypokalemia may also be caused by the paraneoplastic secretion of ectopic adrenocorticotropin hormone.^{155, 156} Spurious hypokalemia (pseudohypokalemia) may occur in patients with acute myeloid leukemia and a marked leukocytosis.¹⁵⁷

Hyperkalemia may result from tumor lysis syndrome.^{158, 159} Less common causes include adrenal insufficiency and drugs (calcineurin inhibitors). Of particular importance is pseudohyperkalemia, usually in the setting of marked leukocytosis or thrombocytosis.¹⁵⁷

Hypophosphatemia can occur with proximal tubular dysfunction (Fanconi syndrome) because of toxic light chains in multiple myeloma.¹⁶⁰ A rare etiology of hypophosphatemia is the syndrome of tumor-induced osteomalacia, in which tumor production of phosphaturic factors, such as fibroblast growth factor 23, results in decreased renal tubular reabsorption of phosphate.¹⁶¹

In patients with multiple myeloma and Waldenström macroglobulinemia, circulating monoclonal proteins can interfere with the laboratory measurement of phosphate, resulting in spuriously elevated serum phosphate levels (pseudohyperphosphatemia).¹⁶²

Hypomagnesemia can be due to gastrointestinal losses or renal tubular dysfunction due to chemotherapy.^{163, 164} Chemotherapeutic agents with hypomagnesemia include cisplatin and cetuximab.^{154, 164}

Cannabinoids, endocannabinoids, and cancer

The psychotropic principle of *Cannabis sativa*, Δ^9 -tetrahydrocannabinol, and its synthetic derivative, nabilone, are already used for nausea induced by chemotherapeutic agents and have also been suggested to reduce cachexia, another possible consequence of cancer.¹⁶⁵ However, the discovery of the mechanism of action of Δ^9 -tetrahydrocannabinol via G protein-coupled receptors, known as cannabinoid receptor type 1 (CB1) and 2 (CB2), and the fact that these receptors are activated by endogenous lipid mediators, known as endocannabinoids, have opened new therapeutic possibilities for several tumors, beyond merely palliative treatments.¹⁶⁶ In fact, the activation of CB1 and/or CB2 by Δ^9 -tetrahydrocannabinol, endocannabinoids, and several synthetic agonists of such receptors was shown to interfere with the growth of several types of solid tumors, including, but not limited to, breast, prostate, and colorectal carcinomas, glioblastoma, as well as skin cancers, including malignant melanomas in vitro and in vivo, in xenograft as well as genetic experimental models.¹⁶⁷ The anticancer action of CB1 and CB2 agonists occurs through several parallel mechanisms, including inhibition of the cell cycle, induction of apoptosis, inhibition of neovascularization, and counteraction of metastatic processes.¹⁶⁸ Furthermore, inhibitors of endocannabinoid enzymatic inactivation were shown to be effective and possibly devoid of the unwanted psychotropic effects of CB1 agonists.¹⁶⁹ More recently, however, nonpsychotropic cannabinoids that act only in part via the endocannabinoid system and hit several molecular targets have been suggested to be effective anticancer agents.¹⁷⁰ Their use as add-on therapies to chemotherapeutic or biological drugs should be considered in future clinical trials.

Future directions and research agenda for onco-nephrology

Onco-nephrology is an emerging and expanding field and, as such, the items to be investigated are numerous. The amount of information is impressive, but this contrasts with our poor understanding of the phenomenon and our limited ability to predict and treat nephrotoxicity.

All nephrologists need to be acquainted with these emerging issues and need to constantly improve their knowledge of the nephrotoxic profile of an increasingly growing number of oncological treatments. In addition, the distinctive issues surrounding the diagnosis and treatment of cancer in patients with kidney disease need additional investigation.

In conclusion, we report a short, nonexhaustive list of subjects for a research agenda, which mirror the topics addressed in the article:

- (i) To explore novel methods to rapidly and easily measure GFR in the field of onco-nephrology;
- (ii) To institute an international registry of cancer in transplanted patients;
- (iii) To understand the higher risk of cancer in CKD, glomerulopathies, and kidney transplant recipients;
- (iv) To verify which subpopulations with TMA might gain advantage from the use of eculizumab or other novel therapies;

- (v) To study approaches for nephroprotection from chemotherapies such as with cisplatin treatment (see, e.g., inhibitors of dipeptidyl peptidase 4 [DPP-4])¹⁷¹;
- (vi) To evaluate new biomarkers for AKI (e.g., neutrophil gelatinase-associated lipocalin [NGAL]) in the field of drug-induced nephrotoxicity and plan possible follow-up protocols; and
- (vii) Early identification of immunotherapy-linked nephrotoxicity.

Disclosure

EAJ is a cofounder, stock holder, and chief of the Medical Advisory Board of Goldilocks Inc. MHR is a member of AbbVie Data Safety Monitoring Board, Retrophin Data Safety Monitoring Board, and Baxter consultant. VDM receives research grants from GW Pharmaceuticals. All the other authors declared no competing interests.

Acknowledgments

The conference was supported by a generous grant from the Menarini International Foundation. EAJ was supported by P30 CA008748, RO1 DK114321, and Byrne Research Funds. FRD received support from National Institutes of Health grants R01 DK078900 and R01 DK091310. GC received support from POR CAMPANIA ICURE CUP B21C17000030007.

The conference received the official endorsement of the following societies: Italian Society of Nephrology (SIN), Italian Association of Medical Oncology (AIOM), European Renal Association – European Dialysis and Transplant Association (ERA-EDTA), and International Society of Nephrology (ISN). The meeting was organized in collaboration with the University of Campania “L. Vanvitelli” and BioGeM.

Appendix

List of the International Conference on Onco-Nephrology Participants

The following people attended the International Conference on Onco-Nephrology held on December 7 to 9, 2017, in Naples, Italy: Ariga Akitaka, Berne, Switzerland; Amit Alahoti, Houston, Texas, USA; Todd R. Alexander, Toronto, Alberta, Canada; Lucia Altucci, Naples, Italy; Hatem Amer, Rochester, Minnesota, USA; Vincenzo Barone, Pisa, Italy; Ariela Benigni, Bergamo, Italy; Luigi Biancone, Turin, Italy; Joseph V. Bonventre, Boston, Massachusetts, USA; Giovanni Camussi, Turin, Italy; Anna Capasso, Denver, Colorado, USA; Fortunato Ciardiello, Naples, Italy; Umberto Capitanio, Milan, Italy; Michele Caraglia, Naples, Italy; Giacomo Carteni, Naples, Italy; Andrés Cervantes, Valencia, Spain; Franco Citterio, Rome, Italy; Laura Cosmai, Milan, Italy; Farhad R. Danesh, Houston, Texas, USA; Bruno Daniele, Benevento, Italy; Antonietta D’Errico, Bologna, Italy; Ferdinando De Vita, Naples, Italy; Vincenzo Di Marzo, Laval, Quebec, Canada; Antonio Ereditato, Berne, Switzerland; Geppino Falco, Naples, Italy; Denis Fouque, Lyon, France; Renato Franco, Naples, Italy; Maurizio Gallieni, Milan, Italy; Giovanni Gambaro, Rome, Italy; Loreto Gesualdo, Bari, Italy; Giuseppe Grandaliano, Foggia, Italy; Calvin Kuo, Stanford, California, USA; Edgar A. Jaimes, New York, New York, USA; Vincent Launay-Vacher, Paris, France; Evaristo Maiello, San Giovanni Rotondo, Italy; Francesca Mallamaci, Reggio Calabria, Italy; Jolanta Malysxko, Bialystok, Poland; Gennaro Marino, Naples, Italy; Erica Martinelli, Naples, Italy; Giuseppe Matarese, Naples, Italy; Takeshi Matsubara, Kyoto, Japan; Piergiorgio Messa, Milan, Italy; Carlo Messina, Milan, Italy; Vincenzo Mirone, Naples, Italy; Floriana

Morgillo, Naples, Italy; Alessandro Nanni Costa, Rome, Italy; Michele Orditura, Naples, Italy; Antonello Pani, Cagliari, Italy; Mark Anthony Perazella, New Haven, Connecticut, USA; Alessandra Perna, Naples, Italy; Claudio Pisano, Ariano Irpino, Italy; Todd Pitts, Denver, Colorado, USA; Camillo Porta, Pavia, Italy; Giuseppe Procopio, Milan, Italy; Qi Qian, Rochester, Minnesota, USA; Giuseppe Remuzzi, Bergamo, Italy; Pierre Ronco, Paris, France; Mitchell H. Rosner, Charlottesville, Virginia, USA; Domenico Russo, Naples, Italy; Lilian L. Siu, Toronto, Ontario, Canada; Walter Stadler, Chicago, Illinois, USA; Francesco Trepiccione, Naples, Italy; Teresa Troiani, Naples, Italy; Davide Viggiano, Ariano Irpino, and Alessandro Weisz, Salerno, Italy; Andrzej Więcek, Katowice, Poland; Ding Xiaoqiang, Shanghai, China; Ortensio Zecchino, Ariano Irpino, Italy; Carmine Zoccali, Reggio Calabria, Italy.

References

1. J. Xu, S.L. Murphy, K.D. Kochanek, et al. Deaths: final data for 2013. *Natl Vital Stat Rep*, 64 (2016), pp. 1-119
2. L. Cosmai, C. Porta, M. Gallieni, et al. Onco-nephrology: a decalogue. *Nephrol Dial Transplant*, 31 (2016), pp. 515-519
3. N. Janus, V. Launay-Vacher, E. Byloos, et al. Cancer and renal insufficiency results of the BIRMA study. *Br J Cancer*, 103 (2010), pp. 1815-1821
4. D.D. Benoit, E.A. Hoste. Acute kidney injury in critically ill patients with cancer. *Crit Care Clin*, 26 (2010), pp. 151-179
5. E. Canet, L. Zafrani, J. Lambert, et al. Acute kidney injury in patients with newly diagnosed high-grade hematological malignancies: impact on remission and survival. *PLoS One*, 8 (2013), Article e55870
6. A.K. Salahudeen, S.M. Doshi, T. Pawar, et al. Incidence rate, clinical correlates, and outcomes of AKI in patients admitted to a comprehensive cancer center. *Clin J Am Soc Nephrol*, 8 (2013), pp. 347-354
7. C.F. Christiansen, M.B. Johansen, W.J. Langeberg, et al. Incidence of acute kidney injury in cancer patients: a Danish population-based cohort study. *Eur J Intern Med*, 22 (2011), pp. 399-406
8. A.B. Libório, K.L. Abreu, G.B. Silva Jr., et al. Predicting hospital mortality in critically ill cancer patients according to acute kidney injury severity. *Oncology*, 80 (2011), pp. 160-166
9. M. Darmon, M. Cioldi, G. Thiery, et al. Clinical review: specific aspects of acute renal failure in cancer patients. *Crit Care*, 10 (2006), p. 211
10. V. Launay-Vacher, S. Oudard, N. Janus, et al. Renal Insufficiency and Cancer Medications (IRMA) Study Group. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. *Cancer*, 110 (2007), pp. 1376-1384
11. V. Launay-Vacher. Epidemiology of chronic kidney disease in cancer patients: lessons from the IRMA study group. *Semin Nephrol*, 30 (2010), pp. 548-556
12. S. Iff, J.C. Craig, R. Turner, et al. Reduced estimated GFR and cancer mortality. *Am J Kidney Dis*, 63 (2014), pp. 23-30
13. S.Y. Na, J.Y. Sung, J.H. Chang, et al. Chronic kidney disease in cancer: an independent predictor of cancer-specific mortality. *Am J Nephrol*, 33 (2011), pp. 121-130

14. M.H. Rosner, M.A. Perazella. Acute kidney injury in patients with cancer. *N Engl J Med*, 376 (2017), pp. 1770-1781
15. M.A. Perazella, R. Dreicer, M.H. Rosner. Renal cell carcinoma for the nephrologist. *Kidney Int*, 94 (2018), pp. 471-483
16. Y. Yang, H.Y. Li, Q. Zhou, et al. Renal function and all-cause mortality risk among cancer patients. *Medicine (Baltimore)*, 95 (2016), p. e3728
17. A.T. Byrne, D.G. Alférez, F. Amant, et al. Interrogating open issues in cancer precision medicine with patient-derived xenografts. *Nat Rev Cancer*, 17 (2017), pp. 254-268
18. H. Gao, J.M. Korn, S. Ferretti, et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. *Nat Med*, 21 (2015), pp. 1318-1325
19. K.M. Leung, G.P. Yeoh, J.K. Chan, et al. Ductal type signet ring cell carcinoma of breast with growth pattern of pure mucinous carcinoma. *Pathology*, 43 (2011), pp. 282-284
20. J.J. Tentler, A.C. Tan, C.D. Weekes, et al. Patient-derived tumour xenografts as models for oncology drug development. *Nat Rev Clin Oncol*, 9 (2012), pp. 338-350
21. M. Hidalgo, F. Amant, A.V. Biankin, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. *Cancer Discov*, 4 (2014), pp. 998-1013
22. R.W. Jenkins, A.R. Aref, P.H. Lizotte, et al. Ex vivo profiling of PD-1 blockade using organotypic tumor spheroids. *Cancer Discov*, 8 (2018), pp. 196-215
23. J. Mestas, C.C. Hughes. Of mice and not men: differences between mouse and human immunology. *J Immunol*, 172 (2004), pp. 2731-2738
24. K. Takao, T. Miyakawa. Genomic responses in mouse models greatly mimic human inflammatory diseases. *Proc Natl Acad Sci U S A*, 112 (2015), pp. 1167-1172
25. J. Seok, H.S. Warren, A.G. Cuenca, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. *Proc Natl Acad Sci U S A*, 110 (2013), pp. 3507-3512
26. N.C. Walsh, L.L. Kenney, S. Jangalwe, et al. Humanized mouse models of clinical disease. *Annu Rev Pathol*, 12 (2017), pp. 187-215
27. L.D. Shultz, B.L. Lyons, L.M. Burzenski, et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. *J Immunol*, 174 (2005), pp. 6477-6489
28. M.W. Melkus, J.D. Estes, A. Padgett-Thomas, et al. Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. *Nat Med*, 12 (2006), pp. 1316-1322
29. P. Lan, N. Tonomura, A. Shimizu, et al. Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus/liver and CD34+ cell transplantation. *Blood*, 108 (2006), pp. 487-492
30. M. Wang, L.C. Yao, M. Cheng, et al. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy. *FASEB J*, 32 (2018), pp. 1537-1549
31. A. Capasso, J. Lang, T.M. Pitts, et al. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts. *J Immunother Cancer*, 7 (2019), p. 37

32. Canadian Cancer Association. Glomerular filtration rate study. Available at: <http://www.cancer.ca> (Accessed March 5, 2019)
33. K. Trobec, L. Knez, P. Meško Brguljan, et al. Estimation of renal function in lung cancer patients. *Lung Cancer*, 76 (2012), pp. 397-402
34. A. Quinton, P. Lewis, P. Ali, et al. A comparison of measured and estimated glomerular filtration rate for carboplatin dose calculation in stage I testicular seminoma. *Med Oncol*, 30 (2013), p. 661
35. R. Cathomas, D. Klingbiel, T.R. Geldart, et al. Relevant risk of carboplatin underdosing in cancer patients with normal renal function using estimated GFR: lessons from a stage I seminoma cohort. *Ann Oncol*, 25 (2014), pp. 1591-1597
36. D. Kaag. Carboplatin dose calculation in lung cancer patients with low serum creatinine concentrations using CKD-EPI and Cockcroft-Gault with different weight descriptors. *Lung Cancer*, 79 (2013), pp. 54-58
37. N.L. Ainsworth, A. Marshall, H. Hatcher, et al. Evaluation of glomerular filtration rate estimation by Cockcroft-Gault, Jelliffe, Wright and Modification of Diet in Renal Disease (MDRD) formulae in oncology patients. *Ann Oncol*, 23 (2012), pp. 1845-1853
38. T. Janowitz, E.H. Williams, A. Marshall, et al. New model for estimating glomerular filtration rate in patients with cancer. *J Clin Oncol*, 35 (2017), pp. 2798-2805
39. L.A. Inker, C.H. Schmid, H. Tighiouart, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. *N Engl J Med*, 367 (2012), pp. 20-29
40. L.A. Stevens, J. Coresh, C.H. Schmid, et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. *Am J Kidney Dis*, 51 (2008), pp. 395-406
41. J.N. Barreto, A.L. McClanahan, A.D. Rule, et al. Incorporating cystatin C to predict methotrexate elimination in patients with CNS lymphoma and suspicious renal function. *Case Rep Hematol*, 2018 (2018), p. 7169897
42. A. Mulaomerović, A. Halilbašić, E. Čičkušić, et al. Cystatin C as a potential marker for relapse in patients with non-Hodgkin B-cell lymphoma. *Cancer Lett*, 248 (2007), pp. 192-197
43. B.A. Molitoris, E.S. Reilly. Quantifying glomerular filtration rates in acute kidney injury: a requirement for translational success. *Semin Nephrol*, 36 (2016), pp. 31-41
44. P. Anastasio, D. Viggiano, M. Zacchia, et al. Delay in renal hemodynamic response to a meat meal in severe obesity. *Nephron*, 136 (2017), pp. 151-157
45. C. Vajdic, M.T. van Leeuwen. Cancer incidence and risk factors after solid organ transplantation. *Int J Cancer*, 125 (2009), pp. 1747-1754
46. P. Piselli, D. Serraino, G.P. Segoloni, et al. Risk of de novo cancers after transplantation. *Eur J Cancer*, 49 (2013), pp. 336-344
47. P. Piselli, G. Busnach, L. Fratino, et al. De novo malignancies after organ transplantation: focus on viral infections. *Curr Mol Med*, 13 (2013), pp. 1217-1222
48. P. O'Donovan, C.M. Perrett, X. Zhang, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. *Science*, 309 (2005), pp. 1871-1874

49. D. Farrugia, S. Mahboob, J. Cheshire, et al. Malignancy-related mortality following kidney transplantation is common. *Kidney Int*, 85 (2014), pp. 1395-1403
50. R. Desai, D. Collett, C.J. Watson. Estimated risk of cancer transmission from organ donor to graft recipient in a national transplantation registry. *Br J Surg*, 101 (2014), pp. 768-774
51. D. Abramowicz, P. Cochat, F.H. Claas, et al. European Renal Best Practice Guideline on kidney donor and recipient evaluation and perioperative care. *Nephrol Dial Transplant*, 30 (2015), pp. 1790-1797
52. G. Stallone, B. Infante, G. Grandaliano. Management and prevention of post-transplant malignancies in kidney transplant recipients. *Clin Kidney J*, 8 (2015), pp. 637-642
53. J. Karalliedde, G. Viberti. Microalbuminuria and cardiovascular risk. *Am J Hypertens*, 17 (2004), pp. 986-993
54. H.L. Hillege, V. Fidler, G.F. Diercks, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. *Circulation*, 106 (2002), pp. 1777-1782
55. A.V. Kshirsagar, A.S. Bombback, H. Bang, et al. Association of C-reactive protein and microalbuminuria (from the National Health and Nutrition Examination Surveys, 1999 to 2004). *Am J Cardiol*, 101 (2008), pp. 401-406
56. G. Leoncini, G. Sacchi, M. Ravera, et al. Microalbuminuria is an integrated marker of subclinical organ damage in primary hypertension. *J Hum Hypertens*, 16 (2002), pp. 399-404
57. Y.S. Lin, F.C. Chiu, J.W. Lin, et al. Association of albuminuria and cancer mortality. *Cancer Epidemiol Biomarkers Prev*, 19 (2010), pp. 2950-2957
58. L. Jorgensen, I. Heuch, T. Jenssen, et al. Association of albuminuria and cancer incidence. *J Am Soc Nephrol*, 19 (2008), pp. 992-998
59. C.P. Wen, K. Matsushita, J. Coresh, et al. Relative risks of chronic kidney disease for mortality and end-stage renal disease across races are similar. *Kidney Int*, 86 (2014), pp. 819-827
60. M. Tonelli, N. Wiebe, B. Culleton, et al. Chronic kidney disease and mortality risk: a systematic review. *J Am Soc Nephrol*, 17 (2006), pp. 2034-2047
61. G. Wong, A. Hayen, J.R. Chapman, et al. Association of CKD and cancer risk in older people. *J Am Soc Nephrol*, 20 (2009), pp. 1341-1350
62. P.H. Weng, K.Y. Hung, H.L. Huang, et al. Cancer-specific mortality in chronic kidney disease: longitudinal follow-up of a large cohort. *Clin J Am Soc Nephrol*, 6 (2011), pp. 1121-1128
63. L. James, G. Wong, J. Craig, et al. Nephrologists' perspectives on cancer screening in patients with chronic kidney disease: an interview study. *Nephrology (Carlton)*, 24 (2019), pp. 414-421
64. M. Assayag, P. Rouvier, M. Gauthier, et al. Renal failure during chemotherapy: renal biopsy for assessing subacute nephrotoxicity of pemetrexed. *BMC Cancer*, 17 (2017), p. 770
65. C.J. Robson, B.M. Churchill, W. Anderson. The results of radical nephrectomy for renal cell carcinoma. *J Urol*, 197 (2017), pp. S111-S113
66. U. Capitanio, F. Montorsi. Renal cancer. *Lancet*, 387 (2016), pp. 894-906
67. E. Scosyrev, E.M. Messing, R. Sylvester, et al. Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904. *Eur Urol*, 65 (2014), pp. 372-377

68. R.J. Motzer, T.E. Hutson, P. Tomczak, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. *N Engl J Med*, 356 (2007), pp. 115-124
69. B. Escudier, A. Pluzanska, P. Koralewski, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. *Lancet*, 370 (2007), pp. 2103-2111
70. G. Hudes, M. Carducci, P. Tomczak, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. *N Engl J Med*, 356 (2007), pp. 2271-2281
71. B.I. Rini, S. Halabi, J.E. Rosenberg, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. *J Clin Oncol*, 26 (2008), pp. 5422-5428
72. C.N. Sternberg, I.D. Davis, J. Mardiak, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. *J Clin Oncol*, 28 (2010), pp. 1061-1068
73. R.J. Motzer, T.E. Hutson, D. Cella, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. *N Engl J Med*, 369 (2013), pp. 722-731
74. R.J. Motzer, D. Nosov, T. Eisen, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. *J Clin Oncol*, 31 (2013), pp. 3791-3799
75. T.K. Choueiri, C. Hessel, S. Halabi, et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update. *Eur J Cancer*, 94 (2018), pp. 115-125
76. B. Escudier, R.J. Motzer, P. Sharma, et al. Treatment beyond progression in patients with advanced renal cell carcinoma treated with Nivolumab in CheckMate 025. *Eur Urol*, 72 (2017), pp. 368-376
77. D.F. McDermott, M.A. Huseni, M.B. Atkins, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. *Nat Med*, 24 (2018), pp. 749-757
78. A.-K.A. Lalani, B.A. McGregor, L. Albiges, et al. Systemic treatment of metastatic clear cell renal cell carcinoma in 2018: current paradigms, use of immunotherapy, and future directions. *Eur Urol*, 75 (2019), pp. 100-110.
79. A. Antonelli, A. Minervini, M. Sandri, et al. Below safety limits, every unit of glomerular filtration rate counts: assessing the relationship between renal function and cancer-specific mortality in renal cell carcinoma. *Eur Urol*, 74 (2018), pp. 661-667
80. U. Capitanio, A. Larcher, M.C. Kriegmair, et al. Do we truly care about the functional outcomes for renal cancer patients? Multidisciplinarity is still far away. *Eur Urol*, 75 (2019), pp. 349-350
81. F. Trevisani, M. Ghidini, A. Larcher, et al. MicroRNA 193b-3p as a predictive biomarker of chronic kidney disease in patients undergoing radical nephrectomy for renal cell carcinoma. *Br J Cancer*, 115 (2016), pp. 1343-1350.
82. M. Zacchia, A. Vilasi, A. Capasso, et al. Genomic and proteomic approaches to renal cell carcinoma *J Nephrol*, 24 (2011), pp. 155-164
83. J.F. Cambier, P. Ronco. Onco-nephrology: glomerular diseases with cancer. *Clin J Am Soc Nephrol*, 7 (2012), pp. 1701-1712

84. V. Jachiet, A. Mekinian, F. Carrat, et al. French Network of systemic and immune disorders associated with hemopathies and cancer (MINHEMON). Autoimmune manifestations associated with lymphoma: characteristics and outcome in a multicenter retrospective cohort study. *Leuk Lymphoma*, 59 (2018), pp. 1399-1405
85. S.A. Birkeland, H.H. Storm. Glomerulonephritis and malignancy: a population-based analysis. *Kidney Int*, 63 (2003), pp. 716-721
86. C. Lefaucheur, B. Stengel, D. Nochy, et al., GN-PROGRESS Study Group. Membranous nephropathy and cancer: epidemiologic evidence and determinants of high-risk cancer association. *Kidney Int*, 70 (2006), pp. 1510-1517
87. H. Beaufils, C. Jouanneau, G. Chomette. Kidney and cancer: results of immunofluorescence microscopy. *Nephron*, 40 (1985), pp. 303-308
88. R.R. Pascal, P.M. Iannaccone, F.M. Rollwagen, et al. Electron microscopy and immunofluorescence of glomerular immune complex deposits in cancer patients. *Cancer Res*, 36 (1976), pp. 43-47
89. Z. Qu, G. Liu, J. Li, et al. Absence of glomerular IgG4 deposition in patients with membranous nephropathy may indicate malignancy. *Nephrol Dial Transplant*, 27 (2012), pp. 1931-1937
90. K.W. Lai, C.L. Wei, L.K. Tan, et al. Overexpression of interleukin-13 induces minimal-change-like nephropathy in rats. *J Am Soc Nephrol*, 18 (2007), pp. 1476-1485
91. K. Taniguchi, H. Fujioka, Y. Torashima, et al. Rectal cancer with paraneoplastic nephropathy: association of vascular endothelial growth factor. *Dig Surg*, 21 (2004), pp. 455-457.
92. E. Tatsis, E. Reinhold-Keller, K. Steindorf, et al. Wegener's granulomatosis associated with renal cell carcinoma. *Arthritis Rheum*, 42 (1999), pp. 751-756
93. M. Ahmed, K. Solangi, R. Abbi, et al. Nephrotic syndrome, renal failure, and renal malignancy: an unusual tumor-associated glomerulonephritis. *J Am Soc Nephrol*, 8 (1997), pp. 848-852
94. J. Mustonen, A. Pasternack, H. Helin. IgA mesangial nephropathy in neoplastic diseases. *Contrib Nephrol*, 40 (1984), pp. 283-291
95. M.A. Perazella. Onco-nephrology: renal toxicities of chemotherapeutic agents. *Clin J Am Soc Nephrol*, 7 (2012), pp. 1713-1721.
96. J.B. Lesesne, N. Rothschild, B. Erickson, et al. Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. *J Clin Oncol*, 7 (1989), pp. 781-789
97. P.J. Medina, J.M. Sipols, J.N. George. Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. *Curr Opin Hematol*, 8 (2001), pp. 286-293
98. H. Izzedine, C. Isnard-Bagnis, V. Launay-Vacher, et al. Gemcitabine-induced thrombotic microangiopathy: a systematic review. *Nephrol Dial Transplant*, 21 (2006), pp. 3038-3045
99. V. Eremina, J.A. Jefferson, J. Kowalewska, et al. VEGF inhibition and renal thrombotic microangiopathy. *N Engl J Med*, 358 (2008), pp. 1129-1136
100. R.M. Touyz, S.M.S. Herrmann, J. Herrmann. Vascular toxicities with VEGF inhibitor therapies—focus on hypertension and arterial thrombotic events. *J Am Soc Hypertens*, 12 (2018), pp. 409-425
101. R. Bellomo, J.A. Kellum, C. Ronco. Acute kidney injury. *Lancet*, 380 (2012), pp. 756-766

102. R.P. Miller, R.K. Tadagavadi, G. Ramesh, et al. Mechanisms of cisplatin nephrotoxicity. *Toxins (Basel)*, 2 (2010), pp. 2490-2518
103. G. Capasso, C. Rosati, F. Ciani, et al. The beneficial effect of atrial natriuretic peptide on cyclosporine nephrotoxicity. *Am J Hypertens*, 3 (1990), pp. 204-210
104. G. Capasso, D.R. Giordano, G. de Tommaso, et al. Parathyroidectomy has a beneficial effect on experimental cisplatin nephrotoxicity. *Clin Nephrol*, 33 (1990), pp. 184-191
105. G. Capasso, D.R. Giordano, N.G. De Santo, et al. The effect of parathyroid hormone on cisplatin nephrotoxicity. *Adv Exp Med Biol*, 252 (1989), pp. 325-329
106. P. Sengupta, S. Basu, S. Soni, et al. Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity. *Proc Natl Acad Sci U S A*, 109 (2012), pp. 11294-11299
107. C. Brooks, Q. Wei, S.G. Cho, et al. Regulation of mitochondrial dynamics in acute kidney injury in cell culture and rodent models. *J Clin Invest*, 119 (2009), pp. 1275-1285
108. M. Marina, P. Luca, R. Cinzia, et al. Sirtuin 3–dependent mitochondrial dynamic improvements protect against acute kidney injury. *J Clin Invest*, 125 (2015), pp. 715-726
109. Z. Yang, L.M. Schumaker, M.J. Egorin, et al. Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: possible role in apoptosis. *Clin Cancer Res*, 12 (2006), pp. 5817-5825
110. M. Zhan, C. Brooks, F. Liu, et al. Mitochondrial dynamics: regulatory mechanisms and emerging role in renal pathophysiology. *Kidney Int*, 83 (2013), pp. 568-581
111. K.M. Ralto, S.M. Parikh. Mitochondria in acute kidney injury. *Semin Nephrol*, 36 (2016), pp. 8-16
112. L. Perico, M. Morigi, A. Benigni. Mitochondrial sirtuin 3 and renal diseases. *Nephron*, 134 (2016), pp. 14-19
113. M. Morigi, L. Perico, A. Benigni. Sirtuins in renal health and disease. *J Am Soc Nephrol*, 29 (2018), pp. 1799-1809
114. M. Morigi, L. Perico, C. Rota, et al. Sirtuin 3-dependent mitochondrial dynamic improvements protect against acute kidney injury. *J Clin Invest*, 125 (2015), pp. 715-726
115. L. Perico, M. Morigi, C. Rota, et al. Human mesenchymal stromal cells transplanted into mice stimulate renal tubular cells and enhance mitochondrial function. *Nat Commun*, 8 (2017), p. 983
116. V.B. Pillai, S. Samant, N.R. Sundaresan, et al. Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial Sirt3. *Nat Commun*, 6 (2015), p. 6656
117. N. Li, H. Xie, L. Li, et al. Effects of honokiol on sepsis-induced acute kidney injury in an experimental model of sepsis in rats. *Inflammation*, 37 (2014), pp. 1191-1199
118. N. Li, J. Zhang, X. Yan, et al. SIRT3-KLF15 signaling ameliorates kidney injury induced by hypertension. *Oncotarget*, 8 (2017), pp. 39592-39604
119. K.A. Hershberger, A.S. Martin, M.D. Hirschey. Role of NAD⁺ and mitochondrial sirtuins in cardiac and renal diseases. *Nat Rev Nephrol*, 13 (2017), pp. 213-225
120. M.S. Bonkowski, D.A. Sinclair. Slowing ageing by design: the rise of NAD⁺ and sirtuin-activating compounds. *Nat Rev Mol Cell Biol*, 17 (2016), pp. 679-690

121. A. Poyan Mehr, M.T. Tran, K.M. Ralto, et al. De novo NAD⁺ biosynthetic impairment in acute kidney injury in humans. *Nat Med*, 24 (2018), pp. 1351-1359
122. H.J. Hammers, E.R. Plimack, J.R. Infante, et al. Immune-related adverse events (irAEs) following CTLA-4 and PD-1/PD-L1 blockade in advanced melanoma: a comprehensive rapid autopsy study. *Mod Pathol*, 29 (2016), p. 4A
123. M.L. Troxell, J.P. Higgins, N. Kambham. Antineoplastic treatment and renal injury: an update on renal pathology due to cytotoxic and targeted therapies. *Adv Anat Pathol*, 23 (2016), pp. 310-329
124. M.H. Rosner, G. Capasso, M.A. Perazella. Acute kidney injury and electrolyte disorders in the critically ill patient with cancer. *Curr Opin Crit Care*, 23 (2017), pp. 475-483
125. S.M. Doshi, P. Shah, X. Lei, et al. Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes. *Am J Kidney Dis*, 59 (2012), pp. 222-228
126. T. Berghmans, M. Paesmans, J.J. Body. A prospective study on hyponatraemia in medical cancer patients: epidemiology, aetiology and differential diagnosis. *Support Care Cancer*, 8 (2000), pp. 192-197
127. G. Gill, B. Huda, A. Boyd, et al. Characteristics and mortality of severe hyponatraemia—a hospital-based study. *Clin Endocrinol (Oxf)*, 65 (2006), pp. 246-249
128. A.H. Ingles Garces, J.E. Ang, M. Ameratunga, et al. A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials. *Eur J Cancer*, 104 (2018), pp. 32-38
129. M.H. Rosner, A.C. Dalkin. Electrolyte disorders associated with cancer. *Adv Chronic Kidney Dis*, 21 (2014), pp. 7-17
130. P. Penttilä, P. Bono, K. Peltola, et al. Hyponatremia associated with poor outcome in metastatic renal cell carcinoma patients treated with everolimus: prognostic impact. *Acta Oncol*, 4 (2018), pp. 1-6
131. J.J. Castillo, I.G. Glezerman, S.H. Boklage, et al. The occurrence of hyponatremia and its importance as a prognostic factor in a cross-section of cancer patients. *BMC Cancer*, 16 (2016), p. 564
132. O.D. Mrowczynski, A.J. Bourcier, J. Liao, et al. The predictive potential of hyponatremia for glioblastoma patient survival. *J Neurooncol*, 138 (2018), pp. 99-104
133. G. Liamis, T.D. Filippatos, M.S. Elisaf. Electrolyte disorders associated with the use of anticancer drugs. *Eur J Pharmacol*, 777 (2016), pp. 78-87
134. R. Berardi, M. Santoni, S. Rinaldi, et al. Risk of hyponatremia in cancer patients treated with targeted therapies: a systematic review and meta-analysis of clinical trials. *PLoS One*, 11 (2016), Article e0152079
135. Y. Enzoe, J. Mizusawa, H. Katayama, et al. An integrated analysis of hyponatremia in cancer patients receiving platinum-based or nonplatinum-based chemotherapy in clinical trials (JCOG1405-A). *Oncotarget*, 9 (2017), pp. 6595-6606
136. R. Berardi, A. Antonuzzo, L. Blasi, et al. Practical issues for the management of hyponatremia in oncology. *Endocrine*, 61 (2018), pp. 158-164
137. L. Holland-Bill, C.F. Christiansen, D.K. Farkas, et al. Diagnosis of hyponatremia and increased risk of a subsequent cancer diagnosis: results from a nationwide population-based cohort study. *Acta Oncol*, 57 (2018), pp. 522-527
138. C. Selmer, J.C. Madsen, C. Toro-Pedersen, et al. Hyponatremia, all-cause mortality, and risk of cancer diagnosis in the primary care setting: a large population study. *Eur J Intern Med*, 36 (2016), pp. 36-43

139. V. Burst, F. Grundmann, T. Kubacki, et al. Euvolemic hyponatremia in cancer patients. Report of the Hyponatremia Registry: an observational multicenter international study. *Support Care Cancer*, 25 (2017), pp. 2275-2283
140. R.J. Gralla, F. Ahmad, J.D. Blais, et al. Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials. *Cancer Med*, 6 (2017), pp. 723-729
141. R. Beradi, M. Santoni, T. Newsom-Davis, et al. Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy. *Oncotarget*, 8 (2017), pp. 23871-23879
142. S. Khositseth, K. Charngkaew, C. Boonkrai, et al. Hypercalcemia induces targeted autophagic degradation of aquaporin-2 at the onset of nephrogenic diabetes insipidus. *Kidney Int*, 91 (2017), pp. 1070-1087
143. A.K. Salahudeen, S.M. Doshi, P. Shah. The frequency, cost and clinical outcomes of hypernatremia in patients hospitalized to a comprehensive cancer center. *Support Care Cancer*, 21 (2013), pp. 1871-1878
144. V.M. Gastanaga, L.S. Schwartzberg, R.K. Jain, et al. Prevalence of hypercalcemia among cancer patients in the United States. *Cancer Med*, 5 (2016), pp. 2091-2100
145. R.E.O. Ramos, M. Perez Mak, M.F.S. Alves, et al. Malignancy-related hypercalcemia in advanced solid tumors: survival outcomes. *J Glob Oncol*, 3 (2017), pp. 728-733
146. F. Zagouri, E. Kastritis, A. Zomas, et al. Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma in the era of novel antineoplastic therapies. *Eur J Hematol*, 99 (2017), pp. 409-414
147. M.H. Rosner, A.C. Dalkin. Onco-nephrology: the pathophysiology and treatment of malignancy-associated hypercalcemia. *Clin J Am Soc Nephrol*, 7 (2012), pp. 1722-1729
148. F.N. Soki, S.I. Park, L.K. McCauley. The multifaceted actions of PTHrP in skeletal metastasis. *Future Oncol*, 8 (2012), pp. 803-817
149. P.J. Donovan, L. Sundac, C.J. Pretorius, et al. Calcitriol-mediated hypercalcemia: causes and course in 101 patients. *J Clin Endocrinol Metab*, 98 (2013), pp. 4023-4029
150. J.J. Wysolmerski. Parathyroid hormone-related protein: an update. *J Clin Endocrinol Metab*, 97 (2012), pp. 2947-2956
151. E.K. O'Donnell, N.S. Raje. Myeloma bone disease: pathogenesis and treatment. *Clin Adv Hematol Oncol*, 15 (2017), pp. 285-295
152. S. Thosani, M.I. Hu. Denosumab: a new agent in the management of hypercalcemia of malignancy. *Future Oncol*, 11 (2015), pp. 2865-2871
153. B. Oronsky, S. Caroen, A. Oronsky, et al. Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management. *Cancer Chemother Pharmacol*, 80 (2017), pp. 895-907
154. J.J. Evans, M.J. Bozdech. Hypokalemia in nonblastic chronic myelogenous leukemia. *Arch Intern Med*, 141 (1981), p. 786
155. D.J. Torpy, N. Mullen, I. Ilias, et al. Association of hypertension and hypokalemia with Cushing's syndrome caused by ectopic ACTH secretion: a series of 58 cases. *Ann N Y Acad Sci*, 970 (2002), p. 134

156. H.Y. Zhang, J. Zhao. Ectopic Cushing syndrome in small cell lung cancer: a case report and literature review. *Thorac Cancer*, 8 (2017), pp. 114-117
157. G. Liamis, E. Liberopoulos, F. Barkas, et al. Spurious electrolyte disorders: a diagnostic challenge for clinicians. *Am J Nephrol*, 38 (2013), pp. 50-57
158. N. Lameire, R. Vanholder, W. Van Biesen, et al. Acute kidney injury in critically ill cancer patients: an update. *Crit Care*, 20 (2016), p. 209
159. M. Criscuolo, L. Fianchi, G. Dragonetti, et al. Tumor lysis syndrome: review of pathogenesis, risk factors and management of a medical emergency. *Expert Rev Hematol*, 9 (2016), pp. 197-208
160. M.Q. Lacy, M.A. Gertz. Acquired Fanconi's syndrome associated with monoclonal gammopathies. *Hematol Oncol Clin North Am*, 13 (1999), pp. 1273-1280
161. S. Minisola, M. Peacock, S. Fukumoto, et al. Tumor-induced osteomalacia. *Nat Rev Dis Primers*, 13 (2017), p. 17044
162. A.J. Lerner. Pseudohyperphosphatemia. *Clin Biochem*, 28 (1985), pp. 391-393
163. G. Cheminet, G. Clain, A.S. Jannot, et al. Extreme hypomagnesemia: characteristics of 119 consecutive inpatients. *Intern Emerg Med*, 13 (2018), pp. 1201-1209
164. H. Izzedine, M.A. Perazella. Adverse kidney effects of epidermal growth factor receptor inhibitors. *Nephrol Dial Transplant*, 32 (2017), pp. 1089-1097
165. M.P. Davis. Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain. *Expert Opin Investig Drugs*, 17 (2008), pp. 85-95
166. M. Bifulco, V. Di Marzo. Targeting the endocannabinoid system in cancer therapy: a call for further research. *Nat Med*, 8 (2002), pp. 547-550
167. G. Velasco, C. Sánchez, M. Guzmán. Endocannabinoids and cancer. *Handb Exp Pharmacol*, 231 (2015), pp. 449-472
168. G. Velasco, C. Sánchez, M. Guzmán. Anticancer mechanisms of cannabinoids. *Curr Oncol*, 23 (2016), pp. S23-S32
169. S. Petrosino, V. Di Marzo. FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. *Curr Opin Investig Drugs*, 11 (2010), pp. 51-62
170. B. Hinz, R. Ramer. Anti-tumour actions of cannabinoids. *Br J Pharmacol*, 176 (2019), pp. 1384-1394
171. Viggiano D, Capasso A, Capasso G. A quest for protecting kidneys from cisplatin toxicity [e-pub ahead of print]. *Nephrol Dial Transplant*. <https://doi-org.pros.lib.unimi.it:2050/10.1093/ndt/gfz029>. Accessed February 27, 2019.

Figure legend

Figure 1. The kidney disease–cancer connection. AKI, acute kidney injury; CKD, chronic kidney disease; ESRD, end-stage renal disorder.

Figure 2. A proposal for a multidisciplinary approach to maximize functional outcomes and quality of life in patients with renal cancer.

Figure 3. Cancer associated with calcium disorders. Both hyper- and hypocalcemia can be associated with an underlying diagnosis of cancer. In each case, specific mechanisms and etiologies are operative. Although hypercalcemia is typically due to the effects of the underlying cancer, hypocalcemia is usually the result of therapeutic maneuvers (surgery, chemotherapies, or radiation therapy). PTH, parathyroid hormone; PTHrP, parathyroid hormone–related protein.

Table 1. First-line setting pivotal trials of targeted systemic therapy in metastatic clear cell renal cell carcinoma⁶

Study	Year	Experimental arm(s)	Control arm(s)	Median overall survival (mo) (HR; 95% CI)
Motzer <i>et al.</i> ⁶⁸	2007	Sunitinib (n = 375)	IFN (n = 375)	26 vs. 21 (0.82; 0.57–1.00)
Escudier <i>et al.</i> ⁶⁹	2007	Bevacizumab + IFN (n = 327)	Placebo + IFN (n = 322)	23 vs. 21 (0.86; 0.72–1.04)
Hudes <i>et al.</i> ⁷⁰	2007	IFN + temsirolimus (n = 210) Temsiroliumus (n = 209)	IFN (n = 207)	8 vs. 11 vs. 7 (0.96; 0.76–1.20 and 0.73; 0.58–0.92)
Rini <i>et al.</i> ⁷¹	2008	Bevacizumab + IFN (n = 369)	IFN (n = 363)	18 vs. 17 (0.86; 0.73–1.01)
Sternberg <i>et al.</i> ⁷²	2010	Pazopanib (n = 290)	Placebo (n = 145)	23 vs. 20 (0.91; 0.71–1.16)
Motzer <i>et al.</i> ⁷³	2013	Pazopanib (n = 557)	Sunitinib (n = 553)	28 vs. 29 (0.92; 0.79–1.06)
Motzer <i>et al.</i> ⁷⁴	2013	Tivozanib (n = 260)	Sorafenib (n = 257)	29 vs. 29 (1.24; 0.95–1.62)
Choueiri <i>et al.</i> ⁷⁵	2018	Cabozantinib (n = 79)	Sunitinib (n = 78)	27 vs. 21 (0.80; 0.53–1.21)
Escudier <i>et al.</i> ⁷⁶	2017	Nivolumab + ipilimumab (n = 550)	Sunitinib (n = 546)	NR vs. 26 (0.63; 0.44–0.89)
Motzer <i>et al.</i> ⁷⁷	2018	Atezolizumab + bevacizumab (n = 454)	Sunitinib (n = 461)	NR vs. 26 (0.63; 0.44–0.89)

CI, confidence interval; HR, hazard ratio; IFN, interferon; NR, not reported.

